Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes
Open accessAbstract
OBJECTIVE—To assess the 12- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 versus placebo in patients with type 2 diabetes continuing metformin treatment. RESEARCH DESIGN AND METHODS—We conducted a 12-week, randomized, double-blind, placebo-controlled trial in 107 patients with type 2 diabetes with a 40-week extension in those completing the core study and agreeing, together with the investigator, to extend treatment to 1 year. Placebo (n = 51) or LAF237 (50 mg once daily, n = 56) was added to ongoing metformin treatment (1,500–3,000 mg/day). HbA1c and fasting plasma glucose (FPG) were measured periodically, and standardized meal tests were performed at baseline, week 12, and week 52. RESULTS—In patients randomized to LAF237, baseline HbA1c averaged 7.7 ± 0.1% and decreased at week 12 (Δ = −0.6 ± 0.1%), whereas HbA1c did not change from a baseline of 7.9 ± 0.1% in patients given placebo (between-group difference in ΔHbA1c = −0.7 ± 0.1%, P < 0.0001). Mean prandial glucose and FPG were significantly reduced in patients receiving LAF237 versus placebo by 2.2 ± 0.4 mmol/l (P < 0.0001) and 1.2 ± 0.4 mmol/l (P = 0.0057), respectively, but plasma insulin levels were not affected. At end point of the extension, the between-group differences in change in mean prandial glucose, insulin, and FPG were −2.4 ± 0.6 mmol/l (P = 0.0001), 40 ± 16 pmol/l (P = 0.0153), and −1.1 ± 0.5 mmol/l (P = 0.0312), respectively. HbA1c did not change from week 12 to week 52 in LAF237-treated patients (n = 42) but increased in participants given placebo (n = 29). The between-group difference in ΔHbA1c after 1 year was −1.1 ± 0.2% (P < 0.0001). CONCLUSIONS—Data from this study demonstrate that LAF237 effectively prevents deterioration of glycemic control when added to metformin monotherapy in type 2 diabetes.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clinical studies of DPPIV inhibitors indicate that this class of drugs improves glycemic control in patients with type 2 diabetes mellitus.
“Clinical studies of DPPIV inhibitors indicate that this class of drugs improves glycemic control in patients with type 2 diabetes mellitus.[35][36][37]”
From Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema (2008) · cites this paper as [36]
Published trials have either not included subjects taking ACEi or have not commented on the inclusion of subjects exposed to ACEis.
“Published trials have either not included subjects taking ACEi or have not commented on the inclusion of subjects exposed to ACEis.[35][36][37][38][39]”
From Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema (2008) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · see citing works
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · see citing works
Åhrén, B., Landin‐Olsson, M., Jansson, P., Svensson, M. K. E., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710 · see citing works
Self-citationVillhauer, E. B., Brinkman, J. A., Naderi, G. B., Burkey, B. F., Dunning, B. E., Prasad, K., Mangold, B. L. K., Russell, M. E., & Hughes, T. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030091l · Cited by 618 · see citing works
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582 · see citing works
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2002-220405 · Cited by 502 · see citing works
Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421 · see citing works
Self-citationFineman, M. S., Bicsak, T. A., Shen, L. Z., Taylor, K., Gaines, E., Varns, A., Kim, D. S., & Baron, A. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2370 · Cited by 353 · see citing works
Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects
Mari, A., Schmitz, O., Gastaldelli, A., Oestergaard, T., Nyholm, B., & Ferrannini, E. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00093.2002 · Cited by 303 · see citing works
Trümper, A., Trümper, K., Trusheim, H., Arnold, R., Göke, B., & Hörsch, D. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.9.0688 · Cited by 238 · see citing works
Sluiter, W. J., Erkelens, D. W., Reitsma, W. D., & Doorenbos, H. (1976) · Diabetes · doi:10.2337/diab.25.4.241 · Cited by 128 · see citing works
Rachman, J., Gribble, F. M., Barrow, B. A., Lévy, J., Buchanan, K. D., & Turner, R. C. (1996) · Diabetes · doi:10.2337/diab.45.11.1524 · Cited by 119 · see citing works
Quddusi, S., Vahl, T. P., Hanson, K., Prigeon, R. L., & D’Alessio, D. A. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.791 · Cited by 111 · see citing works
Trumper, A. (2001) · Molecular Endocrinology · doi:10.1210/me.15.9.1559 · Cited by 90 · see citing works
Sluiter, W. J., Erkelens, D. W., Terpstra, P., Reitsma, W. D., & Doorenbos, H. (1976) · Diabetes · doi:10.2337/diab.25.4.245 · Cited by 79 · see citing works
Bonadonna, R. C., Stümvoll, M., Fritsche, A., Muggeo, M., Häring, H. U., Bonora, E., & van Haeften, T. W. (2003) · Diabetes · doi:10.2337/diabetes.52.2.470 · Cited by 73 · see citing works
Characterization of GLP-1 Effects on β-Cell Function After Meal Ingestion in Humans
Ahrén, B., Holst, J. J., & Mari, A. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2860 · Cited by 72 · see citing works
Self-citationAdditive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes
Zander, M., Taskiran, M., Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.720 · Cited by 60 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [12]12. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Foley JE: LAF237 is a DPP-4 inhibitor that improves model-as- sessed -cell function in drug-naive pa- tients with type 2 diabetes. Diabetologia. In press
Cited by
Sorted by citations
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · see citing works
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · see citing works
Phung, O. J. (2010) · JAMA · doi:10.1001/jama.2010.405 · Cited by 520 · see citing works
Taylor, R. (2013) · Diabetes Care · doi:10.2337/dc12-1805 · Cited by 485 · see citing works
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414 · see citing works
Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369 · see citing works
Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R. (2006) · Diabetologia · doi:10.1007/s00125-006-0340-2 · Cited by 336 · see citing works
Self-citationDipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., & Lerch, C. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006739.pub2 · Cited by 308 · see citing works
Rosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. ‐., Cressier, F., Couturier, A., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00698.x · Cited by 255 · see citing works
Madsen, K., Knudsen, L. B., Agersoe, H., Nielsen, P. F., Thøgersen, H., Wilken, M., & Johansen, N. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070861j · Cited by 244 · see citing works
Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005
Holst, J. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0107-1 · Cited by 228 · see citing works
Liu, S. ‐., Tu, Y. ‐., Chien, M. ‐., & Chien, K. ‐. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01606.x · Cited by 180 · see citing works
Beta cell mass in diabetes: a realistic therapeutic target?
Meier, J. J. (2008) · Diabetologia · doi:10.1007/s00125-008-0936-9 · Cited by 155 · see citing works
Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
Byrd, J. B., Touzin, K., Sile, S., Gainer, J. V., Yu, C., Nadeau, J., Adam, A., & Brown, N. J. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.096552 · Cited by 147 · see citing works
Pharmacologic management of type 2 diabetes
Harper, W., Clement, M., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R., Sherifali, D., Woo, V., & Yale, J.-F. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.021 · Cited by 138 · see citing works
Incretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121 · see citing works
Meier, J. J., Gethmann, A., Nauck, M. A., Götze, O., Schmitz, F., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Holst, J. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00576.2005 · Cited by 104 · see citing works
D'Alessio, D. A., Denney, A. M., Hermiller, L. M., Prigeon, R. L., Martin, J. M., Tharp, W. G., Saylan, M. L., He, Y., Dunning, B. E., Foley, J. E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1135 · Cited by 99 · see citing works
Bioactive peptides from milk: Animal determinants and their implications in human health
Vargas-Bello-Pérez, E., Márquez-Hernández, R. I., & Hernández-Castellano, L. E. (2019) · Journal of Dairy Research · doi:10.1017/s0022029919000384 · Cited by 97 · see citing works
Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis
Amori, R. E., Lau, J., & Pittas, A. G. (2007) · JAMA · doi:10.1001/jama.298.2.194 · Cited by 12 · see citing works
- Authors
- Ahrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A.
- Affiliations
- Lund University, Lund, Sweden
- Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
- Institute of Diabetes Research (DE)
- Novartis (Switzerland) (CH)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2004-12-01
- Volume
- 27
- Issue
- 12
- Pages
- 2874-2880
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1991565451
- Semantic Scholar
- 2a47177776a0ac08bdde56281038a18773846ee4
- Cited by
- 487
- References
- 18
- Citations by year
- 2026: 2 · 2025: 4 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 7 · 2019: 13 · 2018: 2 · 2017: 7 · 2016: 13 · 2015: 11 · 2014: 15 · 2013: 27 · 2012: 14
- FWCI
- 41.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Vetenskapsrådet
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- DPP-4 inhibitors, type 2 diabetes, metformin, combination therapy, glycemic control, HbA1c, fasting blood glucose, insulin, long-term efficacy, extension trial, antidiabetic drugs, adverse events, hypoglycemia
- MeSH terms
- Adamantane, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucose Tolerance Test, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Placebos, Protease Inhibitors, Pyrrolidines, Dipeptidyl Peptidase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
